Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2844 | Anti-Clathrin Heavy Chain / CHC | Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumour activity. MW: 145.62 KD. | Human IgG1 |
| A3100 | Ruplizumab (Anti-TNFSF5 / CD40L / CD154) | Ruplizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized monoclonal antibody targeting CD40L(TNF Receptor). It has the potential for systemic lupus erythematosus disease research. MW :145.68 KD. | Human IgG1 |
| A2845 | Elsilimomab (Anti-IL-6 / IFNb2) | Elsilimomab (Anti-IL-6 / IFNb2) is an IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab has the potential to be used in research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). MW: 145.96 KD. | Human IgG1 |
| A3101 | Vilobelimab (Anti-Complement C5) | Vilobelimab (Anti-Complement C5) is a monoclonal antibody targeting C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. It may be used in studies related to sepsis, COVID-19, etc. MW: 145.9 KD. | Human IgG4SP |
| A2846 | Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) | Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential anti-tumour activity. MW: 143.74 KD. | Human IgG1 |
| A2847 | Lendalizumab (Anti-Complement C5) | Lendalizumab (Anti-Complement C5) is a proprietary antibody that targets the complement protein C5a with potential immunomodulating and anti-inflammatory activities. MW : 146.02 KD. | Human IgG2SA |
| A3103 | Anti-TrkB / NTRK2 | Anti-TrkB / NTRK2 is an antibody targeting TrkB. It is used to improve nerve function, including treatment of peripheral neuropathies. MW: 146.68 KD. | Human IgG2SA |
| A2848 | Enoticumab (Anti-DLL4) | Enoticumab (Anti-DLL4) is a human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity. It has been used to treat advanced solid tumours MW : 146.48 KD. | Human IgG1 |
| A3105 | Anti-TSPAN26 / CD37 (AGS67E) | Anti-TSPAN26 / CD37 (AGS67E) is a fully human monoclonal antibody that targets CD37. It is used for the potential treatment of B/T-cell malignancies. MW: 143.44 KD. | Human IgG2SA |
| A3106 | Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) | Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumours, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW: 145.52 KD. | Human IgG4SP |
| A2851 | Emactuzumab (Anti-CSF1R / M-CSFR / CD115) | Emactuzumab (Anti-CSF1R / M-CSFR / CD115) is a humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R, CSF-1R, CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities MW : 146.94 KD. | Human IgG1 |
| A3107 | Anti-VCAM1 / CD106 | Anti-VCAM1 / CD106 is a conjugated liposome targeting vascular cell adhesion molecule (VCAM)-1. It serves as a drug delivery system with dual functions: targeted delivery and solubilising capacity. MW: 143.4 KD. | Human IgG2SA |
| A2596 | Tilvestamab (Anti-AXL / UFO) | Tilvestamab (Anti-AXL / UFO) is a humanised antibody targeting AXL. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas. MW: 146.16 KD. | Human IgG1 |
| A2852 | Anti-CSF1R / M-CSFR / CD115 (LY3022855) | Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD. | Human IgG1 |
| A3108 | Varisacumab (Anti-VEGFA) | Varisacumab (Anti-VEGFA) is a human recombinant monoclonal antibody targeting VEGFA. It may be used in research of Microvascular complications of diabetes 1 (MVCD1). MW: 145.62 KD. | Human IgG1 |
| A2597 | Alsevalimab (Anti-B7-H4 / VTCN1) | Alsevalimab (Anti-B7-H4 / VTCN1) is a human monoclonal antibody targeting B7-H4. It has potential antineoplastic and immune checkpoint inhibitory activities. MW: 144.74 KD. | Human IgG1 |
| A2853 | Gimsilumab (Anti-CSF2 / GM-CSF) | Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD. | Human IgG1 |
| A3109 | Alacizumab (Anti-VEGFR2 / KDR / CD309) | Alacizumab (Anti-VEGFR2 / KDR / CD309) is a humanised monoclonal antibody targeting VEGFR2 / KDR / CD309. It has anti-tumour effect in tumour growth. MW: 144.08 KD. | Human IgG1 |
| A2598 | Anti-CLEC4C (BIIB059) | Anti-CLEC4C (BIIB059) is a humanized IgG1-κ antibody targeting C-type lectin domain family 4 member C (CLEC4C). It can be used for cutaneous lupus erythematosus (CLE) study. MW: 146.34 KD. | Human IgG1 |
| A2854 | Lenzilumab (Anti-CSF2 / GM-CSF) | Lenzilumab (Anti-CSF2 / GM-CSF) is a recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. MW: 145.72 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.